Hyperlipidemia - Pipeline Review, H1 2015 - Product Image

Hyperlipidemia - Pipeline Review, H1 2015

  • ID: 3106253
  • Report
  • 139 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • BCWorld Pharm Co. Ltd.
  • CJ CheilJedang Corp.
  • CrystalGenomics, Inc.
  • Eli Lilly and Company
  • Huons Co., Ltd.
  • MORE
Hyperlipidemia - Pipeline Review, H1 2015

Summary

This, ‘Hyperlipidemia - Pipeline Review, H1 2015’, provides an overview of the Hyperlipidemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperlipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperlipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • BCWorld Pharm Co. Ltd.
  • CJ CheilJedang Corp.
  • CrystalGenomics, Inc.
  • Eli Lilly and Company
  • Huons Co., Ltd.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hyperlipidemia Overview
Therapeutics Development
Pipeline Products for Hyperlipidemia - Overview
Pipeline Products for Hyperlipidemia - Comparative Analysis
Hyperlipidemia - Therapeutics under Development by Companies
Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes
Hyperlipidemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hyperlipidemia - Products under Development by Companies
Hyperlipidemia - Products under Investigation by Universities/Institutes
Hyperlipidemia - Companies Involved in Therapeutics Development
Ahn-Gook Pharmaceutical Co., Ltd.
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
BCWorld Pharm Co. Ltd.
Catabasis Pharmaceuticals, Inc.
CJ CheilJedang Corp.
CrystalGenomics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Eli Lilly and Company
Esperion Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Huons Co., Ltd.
Isis Pharmaceuticals, Inc.
Jeil Pharmaceutical Co., Ltd.
LG Life Sciences, Ltd.
Michigan Life Therapeutics, LLC
Pfizer Inc.
Pharmena SA
Piramal Enterprises Limited
Prometheon Pharma, LLC
Protalix BioTherapeutics, Inc.
Regeneron Pharmaceuticals, Inc.
TSH Biopharm Corporation Limited
Yuhan Corporation
Hyperlipidemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(atorvastatin calcium + losartan potassium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(atorvastatin calcium + metformin) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(gemigliptin + rosuvastatin calcium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(rosuvastatin calcium + metformin SR) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(rosuvastatin calcium + telmisartan) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGSAA-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-ANG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCWPC-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bempedoic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bococizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BSN-272 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAT-2000 Series - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAT-2003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CG-301269 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSN-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DWJ-1330 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DWJ-1351 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evolocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gemcabene calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HCP-1007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HU-012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-ANGPTL3Rx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JLP-1302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JLP-1401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-3015014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
microRNA-30c for Hyperlipidemia and Atherosclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-7435 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-06427878 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REGN-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-0101870 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Hyperlipidemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRIA-662 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperlipidemia - Recent Pipeline Updates
Hyperlipidemia - Dormant Projects
Hyperlipidemia - Discontinued Products
Hyperlipidemia - Product Development Milestones
Featured News & Press Releases
Nov 18, 2014: Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
Mar 19, 2014: Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia
Mar 05, 2014: Esperion Therapeutics Provides ETC-1002 Program Update
Apr 13, 2012: HanAll BioPharma Initiates Phase I And III Trials Of HL040
Mar 19, 2010: FDA warns about increased risk of muscle injury with Zocor.
Mar 27, 2003: Zocor selected as sole high-potency HMG agent for U.S. Department of Veteran Affairs and Department of Defense.
Nov 05, 1998: Merck announces get-to-goal guarantee for patients taking cholesterol-lowering drug Zocor
Jul 05, 1995: FDA clears Merck's Zocor to save lives, prevent heart attacks; Zocor is first cholesterol-lowering drug available for this use
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hyperlipidemia, H1 2015
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Hyperlipidemia - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015
Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015
Hyperlipidemia - Pipeline by Amgen Inc., H1 2015
Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H1 2015
Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015
Hyperlipidemia - Pipeline by CJ CheilJedang Corp., H1 2015
Hyperlipidemia - Pipeline by CrystalGenomics, Inc., H1 2015
Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015
Hyperlipidemia - Pipeline by Eli Lilly and Company, H1 2015
Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2015
Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H1 2015
Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
Hyperlipidemia - Pipeline by Huons Co., Ltd., H1 2015
Hyperlipidemia - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015
Hyperlipidemia - Pipeline by LG Life Sciences, Ltd., H1 2015
Hyperlipidemia - Pipeline by Michigan Life Therapeutics, LLC, H1 2015
Hyperlipidemia - Pipeline by Pfizer Inc., H1 2015
Hyperlipidemia - Pipeline by Pharmena SA, H1 2015
Hyperlipidemia - Pipeline by Piramal Enterprises Limited, H1 2015
Hyperlipidemia - Pipeline by Prometheon Pharma, LLC, H1 2015
Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H1 2015
Hyperlipidemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015
Hyperlipidemia - Pipeline by TSH Biopharm Corporation Limited, H1 2015
Hyperlipidemia - Pipeline by Yuhan Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hyperlipidemia Therapeutics - Recent Pipeline Updates, H1 2015
Hyperlipidemia - Dormant Projects, H1 2015
Hyperlipidemia - Dormant Projects (Contd..1), H1 2015
Hyperlipidemia - Dormant Projects (Contd..2), H1 2015
Hyperlipidemia - Dormant Projects (Contd..3), H1 2015
Hyperlipidemia - Dormant Projects (Contd..4), H1 2015
Hyperlipidemia - Dormant Projects (Contd..5), H1 2015
Hyperlipidemia - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Hyperlipidemia, H1 2015
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Ahn-Gook Pharmaceutical Co., Ltd.
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
BCWorld Pharm Co. Ltd.
Catabasis Pharmaceuticals, Inc.
CJ CheilJedang Corp.
CrystalGenomics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Eli Lilly and Company
Esperion Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Huons Co., Ltd.
Isis Pharmaceuticals, Inc.
Jeil Pharmaceutical Co., Ltd.
LG Life Sciences, Ltd.
Michigan Life Therapeutics, LLC
Pfizer Inc.
Pharmena SA
Piramal Enterprises Limited
Prometheon Pharma, LLC
Protalix BioTherapeutics, Inc.
Regeneron Pharmaceuticals, Inc.
TSH Biopharm Corporation Limited
Yuhan Corporation
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll